Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

Theravance Biopharma News

Aktie
WKN:  A1137V ISIN:  KYG8807B1068 US-Symbol:  TBPH Branche:  Biotechnologie Land:  USA
16,795 $
+0,055 $
+0,33%
14,329 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
782,93 Mio. €
Streubesitz
-
KGV
160,33
Index-Zuordnung
-

Theravance Biopharma News

30.04.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire
16.04.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire
15.04.26 - PR Newswire
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire
09.04.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH PR Newswire
01.04.26 - PR Newswire
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire
25.03.26 - PR Newswire
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire
19.03.26 - PR Newswire
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update PR Newswire
18.03.26 - PR Newswire
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP PR Newswire
11.03.26 - PR Newswire
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates PR Newswire
03.03.26 - PR Newswire
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions PR Newswire
20.11.25 - PR Newswire
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, ...
19.11.25 - PR Newswire
Theravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma to Participate in Upcoming Investor Conferences PR Newswire
10.11.25 - PR Newswire
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
29.10.25 - PR Newswire
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System PR Newswire
27.10.25 - PR Newswire
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 PR Newswire
14.10.25 - PR Newswire
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting PR Newswire
02.09.25 - PR Newswire
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
25.08.25 - PR Newswire
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to ...
12.08.25 - PR Newswire
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
28.07.25 - PR Newswire
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »